广生堂：目前暂无广生中霖单独运作上市的具体计划

Group 1 - The company has no specific plans for the separate listing of its subsidiary, Guangsheng Zhonglin Biotechnology Co., Ltd. [1] - The recent capital increase in Guangsheng Zhonglin aims to supplement operational funding and accelerate the research and development of innovative drugs, ultimately enhancing the intrinsic value of Guangsheng Zhonglin [1] - The company commits to timely information disclosure in accordance with regulatory requirements, ensuring that all significant information will be announced through designated media [1]